Rx Oversight Issues at Federal Workers’ Comp Program Endangered Patients, Audit Says
Executive Summary
OWCP says that hiring a PBM will address overprescribing and cost concerns, but a consultant who participated in the audit is skeptical.
You may also be interested in...
The Next Big PBM Deal? Rumored Cigna-Humana Talks Raise Overlap Question
Vigorous regulatory scrutiny is a given, but opinions vary about how much the companies’ respective PBM businesses present a major antitrust risk.
Banning Spread Pricing on PBMs Alone May Have Little Impact, Study Suggests
As legislation moves forward in Congress, an examination of high-utilization Part D-covered generic drugs concludes that other payers in the supply chain make almost as much money from spread pricing as PBMs do.
‘Transparency-Rx’: Meet The PBM Execs Breaking Rank And Backing Reforms
New coalition of smaller PBMs champions federal policies requiring ‘100% pass-through’ of rebates, with PBMs then paid by a flat, disclosed fee.